Challenges with integrating early-stage cancer trial endpoints into economic models: review of health technology recommendations for adjuvant or neoadjuvant therapies in Canada
Despite surrogate endpoints and immature survival data, positive reimbursement recommendations were common. CDA-AMC re-analyses frequently had modest impacts on cost-effectiveness. Further guidance is needed to capture benefits and assess uncertainties with more consistency for early-stage cancers.
Authors
- Don Husereau (ORCID: https://orcid.org/0000-0002-4416-6876)
- Sylvie Gosselin (ORCID: https://orcid.org/0000-0003-2188-9112)
- Jaclyn Beca (ORCID: https://orcid.org/0000-0001-8858-9566)
- Eon Ting
Institutions
- University of Ottawa (CA)
- AstraZeneca (Canada) (CA)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1080/14737167.2025.2525224
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca Canada